The GIGA awarded with an European grant from Infect-Era

The GIGA awarded with an European grant from Infect-Era

The GIGA has been recently awarded with an European grant from the 4th call of the Infect-Era. The laboratory of Emmanuel Dejardin, together with research groups from France (Fabien Zoulim, CRCL, and François-Loïc Cosset, CIRI) and Germany (Mathias Heikenwalder, Heidelberg), is involved in a project called Target-HDV.

HDV (Hepatitis Delta Virus) super-infection of chronically HBV-infected patients is the most aggressive chronic form of viral hepatitis, with an accelerated progression towards fibrosis/cirrhosis and an increased risk of liver failure, hepatocellular carcinoma, and death. Around 15-20 millions of people are co-infected with HBV and HDV viruses, ranking this co-infection as one of the most prevalent and most clinically challenging worldwide.

HDV infection is not susceptible to available direct anti-HBV drugs (nucleoside analogs) and suboptimal responses are obtained with IFNα based therapy. Moreover, the number of investigational drugs against HDV infection remains limited; it is mainly due to the fact that (i) HDV does not encode an enzymatic activity, (ii) there are gaps in our knowledge of the HDV viral life cycle and its interaction with HBV, and (iii) until recently no appropriate in vitro model of co-infection to screen for molecules was available.

The goal of this project is to better understand how the NF-kB signaling pathways contribute to the anti-HDV response and to optimize the use of NF-kB inducers for a cure of HDV.

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials